QR code

Use of Janus kinase inhibitors before and after European Medicines Agency safety recommendations: a retrospective study

BackgroundSafety recommendations for Janus kinase inhibitors (JAKi) issued by the European Medical Agency (EMA) in 2023 could potentially influence treatment patterns for rheumatoid arthritis (RA) drugs, but little is known about the impact of these recommendations in routine clinical care.MethodsWe...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Patrick-Pascal Strunz, Linus Maximilian Risser, Matthias Englbrecht, Torsten Witte, Matthias Froehlich, Marc Schmalzing, Michael Gernert, Sebastian Hueper, Peter Bartz-Bazzanella, Cay von der Decken, Kirsten Karberg, Georg Gauler, Susanna Späthling-Mestekemper, Christoph Kuhn, Wolfgang Vorbrüggen, Martin Welcker, Stefan Kleinert
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Frontiers Media S.A. 2024-08-01
Reeks:Frontiers in Immunology
Onderwerpen:
rheumatoid arthritis
cancer
treatment
tumor necrosis factor inhibitors
interleukin-6 receptor inhibitors
oral surveillance
Online toegang:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1445680/full
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items